Journal of Glaucoma

04/11/2002
By Mark Moran

Both latanoprost and brimonidine reduced intraocular pressure in patients with glaucoma or ocular hypertension after six months of treatment, but latanoprost appears to be significantly more effective.

Latanoprost was better tolerated with less frequently occurring ocular allergy and systemic side effects, say researchers at Ludwigs-Maximilians University, Munich, Germany, Fundación Hospital Alcorcón, Madrid, Spain, St. Thomas Hospital, London, England, and Central University Hospital,Turku, Finland.

In a six-month prospective, randomized, observer-masked multicenter study involving 30 eye clinics and 379 patients (of whom 375 were included in analysis), latanoprost monotherapy reduced mean diurnal intraocular pressure by 7.1 ± 3.3 mmHg. Brimonidine monotherapy reduced pressure 5.2 ± 3.5 mmHg, the researchers report.

לכתבה המלאה